Our Private Equity Group is considered the go-to practice for complex, bespoke and firm-defining transactions. With clients ranging from the world’s leading institutional asset managers to prominent middle-market private equity and growth equity firms, we offer comprehensive advice to general partners, limited partners, co-investors and other equity stakeholders, as well as portfolio companies, lenders and financial sponsor groups. The depth and continuity of our relationships across the industry gives us a nuanced understanding of each client’s objectives and allows us to provide seamless, efficient counsel across the investment lifecycle.
eviCore to Be Acquired by Express Scripts for $3.6 Billion
- Client News
- October 10, 2017
As reported by Bloomberg, The Washington Post and other media outlets, Paul, Weiss is representing eviCore healthcare in its $3.6 billion acquisition by Express Scripts Holding Company. Express Scripts is acquiring eviCore from current investors, including General Atlantic, TA Associates and Ridgemont Equity Partners. The transaction, expected to close in the fourth quarter of 2017, is subject to customary regulatory approvals and closing conditions. eviCore is the industry leader in evidence-based medical benefit management services; Express Scripts provides integrated pharmacy benefit management services.
The Paul, Weiss team included, among others, corporate partners Matthew Abbott, Ellen Ching, Dale Sarro and John Kennedy and counsel Scott Grader and Pearl Yuan-Garg; employee benefits partner Robert Fleder and counsel Uri Horowitz; tax partners Patrick Karsnitz, David Mayo and David Sicular; litigation partner Allan Arffa; real estate partner Peter Fisch; intellectual property partner Claudine Meredith-Goujon; environmental counsel William O’Brien; and antitrust counsel Marta Kelly.